- Home
- Prevention
Prevention
Severe Hypertriglyceridaemia: Defining the Disease and Its Management
- 1.00
Published:
Learning objectives
- Recall the mechanisms that make TGs a risk factor for atherosclerosis
- Review how elevated FCS is a major risk factor for pancreatitis
- Discuss the current clinical evidence of TG-lowering therapies in different disease states
Targeting Residual Inflammatory Risk: The Future of Cardiovascular Prevention
- 1.00
Published:
Learning objectives
- Define residual inflammatory risk (RIR) and explain why cardiovascular events continue to occur in patients despite optimal lipid-lowering and antihypertensive therapies
- Describe the pathophysiological role of inflammation in atherosclerosis, myocardial infarction, heart failure and chronic kidney disease
- Identify patients at increased cardiovascular risk due to elevated inflammatory markers, particularly high-sensitivity C-reactive protein (hsCRP)
- Interpret the clinical significance of hsCRP and other inflammatory biomarkers in primary and secondary prevention settings, in alignment with current evidence and guideline recommendations
- Assess clinician practices, barriers and strategies for integrating inflammatory risk assessment and management
- Apply key takeaways to inform future risk assessment and treatment decisions in patients with or at risk for cardiovascular disease
Revolutionising Thrombosis Treatment in ACS, SSP and AF
- 1.00
Published:
Learning objectives
- Discuss the unmet needs in thrombosis management, MACE burden after ACS, stroke in AF and secondary stroke prevalence and consequences
- Evaluate the current standard of care for the treatment of ACS, SSP and AF and its limitations
- Review guidelines and critique current prescribing practices and the implications of inadequate treatment
- Explain the different strategies for targeting FXI and how FXI inhibition mechanisms differentiate from traditional anticoagulation therapies
- Identify emerging anticoagulant strategies and describe the efficacy and safety data from Phase 2 FXI inhibitor clinical trials as well as ongoing Phase 3 trials and potential place in therapy for ACS, AF and SSP
- Apply evidence-based anticoagulation strategies by optimising treatment decisions and addressing patient-specific risk factors
The Rise of CVRM Medicine: Managing Common Co-morbidities as One
- 3.00
Published:
Learning objectives
- Describe the link between T2DM, CKD and ASCVD
- State the importance of early and effective intervention in managing CVRM disease progression
- List the guideline directed therapeutic targets in CVRM disease
- Select appropriate patients for holistic CVRM management
- Recall trial data for novel therapeutic agents that carry benefit for CVRM outcomes
- Develop a holistic management strategy for CVRM disease with an evidence-based impact on clinical outcomes
Managing Hypertension in CVD: How Low Can We Go?
- 1.00
Published:
Learning objectives
- Describe the link between CVD and hypertension
- Classify hypertension patients according to their cardiovascular risk
- Recall recent guideline-directed and evidence-based strategies for managing very high CVD risk patients
- Apply guideline-directed and evidence-based management strategies to a case study
- Use expert guidance to adopt optimal multidisciplinary antihypertensive management strategies in patients with very high cardiovascular risk
Advancements in Triglyceride-lowering Therapies
- 1.00
Published:
Learning objectives
- Recall the primary and secondary outcomes from key triglyceride-lowering trials presented during ESC 2024
- Discuss the current and future implication of trial results to clinical management and practice guidelines
